Q-omics provides the consensus-scored C5orf24 profile across patient tissues and cancer cell-line models. C5orf24 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, C5orf24 is differentially expressed in 9, with the highest sampling consensus in LUSC. Additionally, C5orf24 protein abundance shows 22,006 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, LUSC, and GBM as cancer lineages where C5orf24 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C5orf24 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C5orf24 survival associations across molecular data types. C5orf24 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C5orf24 RNA expression–survival associations across cancer types. High C5orf24 expression shows unfavorable associations in UVM, KICH, CESC and KIRP, but favorable associations in KIRC and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for C5orf24 RNA expression.
This table summarizes C5orf24 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in LUSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for C5orf24. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C5orf24 shows lower tumor expression in LUSC, KICH, LUAD and THCA and higher tumor expression in LIHC and HNSC. The LUSC box plot shows higher C5orf24 RNA expression in normal versus tumor tissue (log2 FC = −0.615, t-test p < 0.001).
This table shows molecular features associated with C5orf24 in patient tissues and cancer cell lines. In patient samples, C5orf24 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, C5orf24 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in LIVER and OESOPHAGUS.
